Amgen's Second Quarter 2026 Financial Results Show Robust Growth and Continued Innovation

Amgen Reports Strong Second Quarter Financial Results for 2026

On August 4, 2026, Amgen (NASDAQ: AMGN) published its financial results for the second quarter of 2026. The company reported a notable performance, marked by a 10% increase in total revenues, reaching $10.1 billion compared to the same period last year. Robert A. Bradway, Amgen's CEO, attributed this growth to the success of six key growth drivers, which together contributed approximately 70% of the product sales for the quarter.

Financial Highlights

Amgen's robust balance sheet shows significant movement, driven by a 9% increase in product sales. Product lines such as Repatha® and EVENITY® achieved remarkable year-over-year sales growth of 37% and 38%, respectively. In particular, 22 products experienced double-digit sales growth in Q2, showcasing a healthy market demand for Amgen's offerings.

The company recorded a 65% increase in GAAP earnings per share (EPS) from $2.65 to $4.37 due to heightened revenues. Their GAAP operating income also surged from $2.7 billion to $3.5 billion, resulting in an operating margin lift to 36.8%. Non-GAAP EPS demonstrated a more modest 4% increase, moving from $6.02 to $6.29. Still, total non-GAAP operating income rose from $4.3 billion to $4.6 billion.

Amgen generated an impressive $3.5 billion in free cash flow during the quarter, significantly higher than last year’s $1.9 billion. This positive shift reflects not only immediate performance but also strategic investments and operational efficiency.

Product Performance Insights

Amgen's detailed performance highlights in its product portfolio tell an impressive story of growth. In the General Medicine sector, sales of Repatha® and EVENITY® drove substantial revenue increases, while Prolia®'s sales were impacted by emerging biosimilar competition—a 32% decrease year-on-year.

In the Rare Disease division, sales of UPLIZNA® skyrocketed by 90%, illustrating effective market penetration and demand, whereas TEPEZZA® and KRYSTEXXA® also enjoyed favorable growth rates. Amgen’s TAVNEOS®, after gaining FDA approval in 2021, continues to evolve amidst regulatory review discussions, indicating a proactive approach in managing market presence.

Investments in Future Growth

Amgen is firmly placed on the path to future innovation, as outlined by its diverse pipeline. The company announced a range of ongoing clinical trials, especially in chronic weight management therapies like MariTide, aimed at improving patient health outcomes. Through various Phase 3 studies currently in progress, Amgen is expanding the potential indications for its existing medicines while also advancing new molecules.

The pipeline also includes other promising candidates like Olpasiran, targeting cardiovascular challenges, and Dazodalibep, which is undergoing trials for autoimmune conditions—showcasing Amgen’s commitment to addressing a variety of health issues with innovative solutions.

As the biotechnology industry continues to evolve, Amgen is strategically investing in its product pipeline, setting the stage for longer-term growth. With a stable market presence and a focus on leveraging cutting-edge technology, Amgen is well-positioned to navigate the future while delivering innovative solutions to patients worldwide.

Conclusion

Amgen’s financial performance for the second quarter of 2026 not only reflects its current market strength but also fuels optimism for upcoming periods. The company is enhancing its operational strategies while continuing to explore new opportunities for growth, reaffirming its position as a leader in the biotechnology field. As it stands, Amgen is paving the way for continued influence in healthcare innovation and shareholder value.